MedCity News
NOVEMBER 1, 2022
Large employers, particularly self-insured companies, can demand a better and fairer system. They can use their contracting power to insist that their plans cover all FDA approved drugs.
PharmaVoice
NOVEMBER 1, 2022
Leaders at Veeva believe the wording around decentralized trials has been exaggerated, and that a bigger-picture outlook is important as the pandemic winds down.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
NOVEMBER 1, 2022
With the money, Daye is looking to reach more people with its products and services, whether that’s in the U.S., U.K. or Europe, Milanova said. The company will also expand research in gynecological health, focusing on conditions like endometriosis, PCOS and menopause. .
European Pharmaceutical Review
NOVEMBER 1, 2022
Bristol Myers Squibb (BMS) has announced Reblozyl ® (luspatercept-aamt), the first erythroid maturation agent, showed improvement in red blood cell transfusion independence (RBC-TI) and haemoglobin (Hb) increase in severely anaemic adults with very low, low or intermediate-risk myelodysplastic syndromes (MDS). Reblozyl is a first-line therapy that promotes late-stage red blood cell maturation in animal models.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
MedCity News
NOVEMBER 1, 2022
As digital health gains popularity, the survey provides payers and other healthcare stakeholders with key information on consumers’ preferences when it comes to virtual primary care.
Medgadget
NOVEMBER 1, 2022
A team of researchers at the University of Tsukuba in Japan has developed a fluffy soft robot that patients can interact with to reduce their stress and fear when undergoing painful or uncomfortable medical procedures. For some patients, particularly children, a fear of needles or uncomfortable and painful procedures can make such experiences especially challenging, and may mean that they attempt to avoid treatment altogether.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Legacy MEDSearch
NOVEMBER 1, 2022
CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, announced it has received 510(k) clearance (K222505) from the U.S. Food & Drug Administration (FDA) for its smaller-diameter CurvaFix® IM Implant indicated for fixation of fractures of the pelvis. The new 7.5mm device is designed to simplify surgery and to provide strong, stable, curved fixation in smaller patients.
MedCity News
NOVEMBER 1, 2022
Cresilon, a startup that makes a hemostatic gel to stop bleeding, has raised $25 million in a Series A-4 financing round. The round brings the company’s total funding to date to nearly $82 million. The funds will help support Cresilon’s entrance into the human health market, as its gel is currently used only by veterinarians.
pharmaphorum
NOVEMBER 1, 2022
In January 2020, the financial conglomerate Visa announced it was acquiring a relatively unknown startup, Plaid, for $5.3 billion. Corporate acquisitions like these are not uncommon, but someone at the United States Department of Justice took notice of this announcement. Visa had established a stranglehold on financial transactions. The Justice Department moved to stop the acquisition on grounds that Plaid posed “a threat to this monopoly: it has been developing an innovative new solution that w
MedCity News
NOVEMBER 1, 2022
Pfizer’s respiratory syncytial virus vaccine candidate infants has clinical data showing it helped prevent severe infections in infants. It’s a maternal vaccine that produces antibodies in the mother that confer temporary protection to a baby.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
NOVEMBER 1, 2022
FEATURED COMPANIES COMMENDED : • Innovation • Product Launch • Safety VIEW PROFILE COMMENDED : • Business Expansion • Innovation • Investments VIEW PROFILE COMMENDED: • Social VIEW PROFILE. The Excellence Rankings celebrate the greatest achievements and innovations in the industry. The programme provides a platform to recognise the people and companies that are driving change.
MedCity News
NOVEMBER 1, 2022
To successfully implement an internal staffing or travel agency that may span multiple cities or states, organizations need the technology and data available to support this endeavor.
European Pharmaceutical Review
NOVEMBER 1, 2022
Researchers from Qingdao University of Science and Technology, China have used artificial intelligence (AI) to predict compounds that could neutralise baldness-causing reactive oxygen species in the scalp. Using the best candidate, they constructed a proof-of-concept microneedle patch and effectively regenerated hair on mice. Reporting in ACS’ Nano Letters , about the condition androgenic alopecia , the researchers explained that hair follicles can be damaged by androgens, inflammation or an ov
MedCity News
NOVEMBER 1, 2022
A patient affected by a data breach at Advocate Aurora Health has sued the healthcare […].
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
PharmExec
NOVEMBER 1, 2022
Ten-year partnership will help Merck reduce operational costs, deliver value to patients, and optimize the healthcare professional and patient experience.
MedCity News
NOVEMBER 1, 2022
As a nation, let’s face our alcohol dependency head-on and have an honest discussion about the growing consumption trends.
Medgadget
NOVEMBER 1, 2022
Avenda Health , a medtech company based in Santa Monica, California has developed the FocalPoint ablation system, an AI-powered prostate cancer therapy. The system is designed to provide localized prostate cancer treatment and its AI system equips clinicians with a map of a patient’s cancer, along with treatment simulations to help them chose the best course of action.
MedCity News
NOVEMBER 1, 2022
Human Immunology Bioscience aims to stand apart in autoimmune disease drug research with therapies that address cells at the root of a range of allergic and inflammatory disorders. The biotech has a lead program licensed from MorphoSys in clinical development for two rare kidney diseases and $120 million to support that antibody and other biologic drugs in its pipeline.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
European Pharmaceutical Review
NOVEMBER 1, 2022
Patients 65 years or older, those with increased risk of cardiovascular disorders like heart attack or stroke, individuals who smoke or have for an extended period in the past and those at increased risk of cancer should only be given Janus kinase (JAK) inhibitors if no other suitable treatment is available, recommends the European Medicines Agency (EMA)’s Pharmacovigilance Risk Assessment Committee (PRAC).
PharmaVoice
NOVEMBER 1, 2022
The Bill & Melinda Gates Medical Research Institute’s clinical development leader talks about its new licensing deal with Merck.
Copyright Clearance Center
NOVEMBER 1, 2022
The post Why Scientific Literature and Copyright Compliance Are Essential to Medical Affairs appeared first on Copyright Clearance Center.
PharmaTimes
NOVEMBER 1, 2022
CamPROBE may save vital time and money while reducing the risk of infection
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Pharmaceutical Technology
NOVEMBER 1, 2022
Intrinsic Medicine has signed a definitive business combination agreement with special purpose acquisition (SPAC) firm Phoenix Biotech Acquisition to create a public company. The merged business will use human milk biology for the treatment of Gut-Brain Axis (GBA) disorders. The merger reflects a $136m pre-money equity price and is anticipated to offer up to $178.8m in cash held in trust to Intrinsic. .
Spotio
NOVEMBER 1, 2022
Let’s talk about the “R” word. Just mentioning it in passing has the potential to make even the most seasoned sales professional nervous. Whether or not you think we are in the middle of one today or sometime in the future, basic economics teaches us that what goes up must come down and that an economic downturn is inevitable. For those that have gone through recessions, this may conjure up some unpleasant memories.
Pharmaceutical Technology
NOVEMBER 1, 2022
The number one mechanism of action (MoA) for the Alzheimer’s disease (AD) pipeline is the inhibition of amyloid plaque formation. However, according to new research by the University of Cincinnati, amyloid plaques may not be the major cause of AD as previously thought—so are they the best target? AD is the leading cause of dementia, which is an umbrella term for a series of syndromes that can lead to memory loss, cognitive decay and behavioural change.
LEVO Health
NOVEMBER 1, 2022
Pharmaceutical brands often take a backseat role in patient health by encouraging patients to talk to their healthcare provider about treatment options. However, today’s healthcare consumers are asking for a different approach. Instead of spending hours on search engines looking for a healthcare provider, consumers now look to drug manufacturers, pharmaceutical companies, and other health-related brands to provide them with resources to make informed decisions. .
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
KBK Communications
NOVEMBER 1, 2022
The healthcare industry is a very competitive and complex environment. The market is growing at an exponential rate, but there are market development and growth opportunities that are not yet fully realized by most businesses. This means that there are lots of opportunities for those who want to succeed in this industry.
pharmaphorum
NOVEMBER 1, 2022
One of the greatest commodities in the healthcare industry is the provision of medically relevant information to enable critical decision-making that ultimately optimizes patient outcomes. This is especially true when it comes to medical communications and scientific engagement. However, when working with complex stakeholder groups and large datasets in an increasingly saturated information and digital landscape, it can be hard to understand who your audience is and the best way to engage it.
Pharmaceutical Technology
NOVEMBER 1, 2022
FEATURED COMPANIES COMMENDED : • Innovation • Product Launch • Safety VIEW PROFILE COMMENDED : • Business Expansion • Innovation • Investments VIEW PROFILE COMMENDED: • Social VIEW PROFILE. The Excellence Rankings celebrate the greatest achievements and innovations in the industry. The programme provides a platform to recognise the people and companies that are driving change.
PharmaTech
NOVEMBER 1, 2022
In this episode, Alivia Leon, assistant editor, speaks with Christian Dunne, director of global corporate business development, Chargepoint Technology, about current and future processing equipment trends, such as automation, cost, and sustainability.
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
143 
Let's personalize your content